The assessment of parameters of convalescent plasma and their impact on COVID-19 symptoms
Agnieszka Kuś
Profil Orcid, Szymon Wieczorek
Profil Orcid, Jarosław Dybko
Profil Orcid, Małgorzata Szymczyk-Nużka
Profil Orcid, Aleksandra Butrym
Profil Orcid, Krzysztof Dudek
Profil Orcid, Grzegorz Mazur
Profil Orcid et Siddarth Agrawal
Profil Orcid 
Catégorie d'article: Original Study
Publié en ligne: 17 avr. 2025
Pages: 35 - 49
Reçu: 29 juil. 2024
Accepté: 19 févr. 2025
DOI: https://doi.org/10.2478/ahem-2025-0006
Mots clés
© 2025 Agnieszka Kuś et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Background
The rapid spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, known as COVID-19, has been a dreadful public health problem with no specific treatment strategy. Using convalescent plasma (CP) with neutralizing antibodies has been analyzed as a potential strategy to reduce mortality and the severity of illness.
Materials and Methods
Our open-label, multi-center, single-arm trial aimed to evaluate the effects of CP transfusion and the risk factors for mortality following CP among 108 COVID-19-infected patients. Each patient was transfused with 200 mL of CP with a confirmed neutralization activity from 44 recovered donors. The efficacy of COVID-19 treatment was defined as the desired change in clinical parameters after CP administration.
Results
Our results showed that leukocyte counts increased significantly after CP transfusion (p < 0.001), and hemoglobin levels improved over time (
Conclusions
Overall, these findings contribute to optimizing COVID-19 treatment approaches, providing valuable information on the effectiveness of convalescent plasma therapy and its associated factors.